Not applicableAvailableNCT05067166
What this trial is testing
Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP
Who this might be right for
Ebola Virus Disease
Ridgeback Biotherapeutics, LP